Dr. Stephanie Blank, MD

Claim this profile

Mount Sinai Hospital

Studies Uterine Cancer
Studies Endometrial Cancer
5 reported clinical trials
10 drugs studied

Area of expertise

1Uterine Cancer
Stephanie Blank, MD has run 3 trials for Uterine Cancer. Some of their research focus areas include:
Stage III
Stage IV
HER2 positive
2Endometrial Cancer
Stephanie Blank, MD has run 3 trials for Endometrial Cancer. Some of their research focus areas include:
Stage III
Stage IV
HER2 positive

Affiliated Hospitals

Image of trial facility.
Mount Sinai Hospital
Image of trial facility.
Mount Sinai Chelsea

Clinical Trials Stephanie Blank, MD is currently running

Image of trial facility.

ACR-368

for Ovarian Cancer

This trial tests a new drug, ACR-368, alone or with a small dose of another drug, gemcitabine, in patients whose cancers don't respond to standard treatments. A special test helps decide which treatment might work best for each patient. Gemcitabine has been used with other drugs for various cancers, including pancreatic, lung, ovarian, and breast cancers.
Recruiting1 award Phase 1 & 210 criteria
Image of trial facility.

Herceptin Hylecta or Phesgo + Chemotherapy

for Uterine Cancer

This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting1 award Phase 2 & 3

More about Stephanie Blank, MD

Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Stephanie Blank, MD has experience with
  • Carboplatin
  • Paclitaxel
  • ACR-368
  • Gemcitabine
  • AK104
  • Bilateral Salpingectomy With Oophorectomy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stephanie Blank, MD specialize in?
Stephanie Blank, MD focuses on Uterine Cancer and Endometrial Cancer. In particular, much of their work with Uterine Cancer has involved Stage III patients, or patients who are Stage IV.
Is Stephanie Blank, MD currently recruiting for clinical trials?
Yes, Stephanie Blank, MD is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Stephanie Blank, MD has studied deeply?
Yes, Stephanie Blank, MD has studied treatments such as Carboplatin, Paclitaxel, ACR-368.
What is the best way to schedule an appointment with Stephanie Blank, MD?
Apply for one of the trials that Stephanie Blank, MD is conducting.
What is the office address of Stephanie Blank, MD?
The office of Stephanie Blank, MD is located at: Mount Sinai Hospital, New York, New York 10011 United States. This is the address for their practice at the Mount Sinai Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.